Recent research found that GPX4 was reduced in HFpEF mice with obesity and impaired glucose tolerance, and imeglimin treatment not only improved their abnormal systemic glucose metabolism and visceral obesity, but also suppressed the upregulation of iNOS and restored expression of Xbp1s and GPX4 [70]. This evidence concerns the gene GPX4 and obesity due to melanocortin 4 receptor deficiency.